Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis

被引:33
|
作者
Chen, Ying [1 ]
Huang, Lan [1 ]
Dong, Yongjian [1 ]
Tao, Changli [1 ]
Zhang, Rongxin [1 ]
Shao, Hongwei [1 ]
Shen, Han [1 ]
机构
[1] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Guangdong Prov Key Lab Biotechnol Drug Candidates, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT1; E17K; mutation; cancer; prognisis; PLECKSTRIN HOMOLOGY DOMAIN; KINASE INHIBITOR P27(KIP1); SQUAMOUS-CELL CARCINOMA; E3; LIGASE; ONCOGENIC MUTATION; PIK3CA MUTATIONS; HUMAN BREAST; AKT1(E17K) MUTATIONS; ACTIVATING MUTATION; INSULIN-RECEPTOR;
D O I
10.3389/fcell.2020.573599
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The substitution of the seventeenth amino acid glutamate by lysine in the homologous structural domain of the Akt1 gene pleckstrin is a somatic cellular mutation found in breast, colorectal, and ovarian cancers, named p. Glu17Lys or E17K. In recent years, a growing number of studies have suggested that this mutation may play a unique role in the development of tumors. In this review article, we describe how AKT1(E17K) mutations stimulate downstream signals that cause cells to emerge transformed; we explore the differential regulation and function of E17K in different physiological and pathological settings; and we also describe the phenomenon that E17K impedes tumor growth by interfering with growth-promoting and chemotherapy-resistant AKT1(low)QCC generation, an intriguing finding that mutants may prolong tumor patient survival by activating feedback mechanisms and disrupting transcription. This review is intended to provide a better understanding of the role of AKT1(E17K) in cancer and to inform the development of AKT1(E17K)-based antitumor strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients
    de Bruin, Elza C.
    Whiteley, Jessica L.
    Corcoran, Claire
    Kirk, Pauline M.
    Fox, Jayne C.
    Armisen, Javier
    Lindemann, Justin P. O.
    Schiavon, Gaia
    Ambrose, Helen J.
    Kohlmann, Alexander
    PLOS ONE, 2017, 12 (05):
  • [22] A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1
    Deyle K.M.
    Farrow B.
    Qiao Hee Y.
    Work J.
    Wong M.
    Lai B.
    Umeda A.
    Millward S.W.
    Nag A.
    Das S.
    Heath J.R.
    Nature Chemistry, 2015, 7 (5) : 455 - 462
  • [23] Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting
    Do H.
    Solomon B.
    Mitchell P.L.
    Fox S.B.
    Dobrovic A.
    BMC Research Notes, 1 (1)
  • [24] A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1
    Deyle, Kaycie M.
    Farrow, Blake
    Hee, Ying Qiao
    Work, Jeremy
    Wong, Michelle
    Lai, Bert
    Umeda, Aiko
    Millward, Steven W.
    Nag, Arundhati
    Das, Samir
    Heath, James R.
    Nature Chemistry, 2015, 7 (05) : 455 - 462
  • [25] AKT1 (E17K) mutation: coexistence with oncogenic alterations, prevalence, and correlation to clinical parameter in a large series of breast cancer patients
    Rudolph, Marion
    Anzeneder, Tobias
    Ocker, Matthias
    Lagkadinou, Eleni
    Politz, Oliver
    Michels, Martin
    Schulz, Anke
    Beckmann, Georg
    Teufel, Michael
    Seidel, Henrik
    Soong, Richie
    Bodenmueller, Heinz
    Ohlms, Ulla
    Asadullah, Khusru
    Reischl, Joachim
    CANCER RESEARCH, 2014, 74 (19)
  • [26] The oncogenic E17K mutation in the pleckstrin homology domain of AKT1 significantly promotes v-ABL-mediated cellular transformation
    Chen, Jilong
    Li, Zhiguo
    Qiao, Zhenzhen
    Wang, Zixu
    Chen, Yaoxing
    CANCER RESEARCH, 2009, 69
  • [27] Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver
    Riener, M-O
    Bawohl, M.
    Clavien, P-A
    Jochum, W.
    BRITISH JOURNAL OF CANCER, 2008, 99 (05) : 836 - 836
  • [28] Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver
    M-O Riener
    M Bawohl
    P-A Clavien
    W Jochum
    British Journal of Cancer, 2008, 99 : 836 - 836
  • [29] Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
    J Lauring
    D P Cosgrove
    S Fontana
    J P Gustin
    H Konishi
    A M Abukhdeir
    J P Garay
    M Mohseni
    G M Wang
    M J Higgins
    D Gorkin
    M Reis
    B Vogelstein
    K Polyak
    M Cowherd
    P J Buckhaults
    B H Park
    Oncogene, 2010, 29 : 2337 - 2345
  • [30] Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
    Lauring, J.
    Cosgrove, D. P.
    Fontana, S.
    Gustin, J. P.
    Konishi, H.
    Abukhdeir, A. M.
    Garay, J. P.
    Mohseni, M.
    Wang, G. M.
    Higgins, M. J.
    Gorkin, D.
    Reis, M.
    Vogelstein, B.
    Polyak, K.
    Cowherd, M.
    Buckhaults, P. J.
    Park, B. H.
    ONCOGENE, 2010, 29 (16) : 2337 - 2345